Who are LipoCol Forte capsules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crestor, Lipitor, FLUVASTATIN SODIUM, Lescol, pioglitazone + simvastatin, statin + ezetimibe.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lipocol-forte-capsules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

LipoCol Forte capsules — Competitive Intelligence Brief

LipoCol Forte capsules (LipoCol Forte capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin combination / Lipid-lowering agent. Area: Cardiovascular.

marketed Statin combination / Lipid-lowering agent HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

LipoCol Forte capsules (LipoCol Forte capsules) — National Taiwan University Hospital. LipoCol Forte reduces cholesterol levels by inhibiting HMG-CoA reductase and enhancing cholesterol clearance through multiple lipid-lowering pathways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LipoCol Forte capsules TARGET	LipoCol Forte capsules	National Taiwan University Hospital	marketed	Statin combination / Lipid-lowering agent	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
pioglitazone + simvastatin	pioglitazone + simvastatin	University of Leipzig	marketed	Thiazolidinedione + HMG-CoA reductase inhibitor combination	PPAR-γ (pioglitazone); HMG-CoA reductase (simvastatin)
statin + ezetimibe	statin + ezetimibe	University of Roma La Sapienza	marketed	Lipid-lowering agent combination (statin + cholesterol absorption inhibitor)	HMG-CoA reductase; NPC1L1 transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (Statin combination / Lipid-lowering agent class)

National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LipoCol Forte capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/lipocol-forte-capsules. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab